# NVS fair value — Novartis AG ADR

Equity Rank model valuation · Drug Manufacturer · as of 2026-09-18
Source: https://www.equity-rank.com/stocks/NVS  ·  JSON: https://api.equity-rank.com/api/stocks/NVS/public

As of 2026-09-18, Novartis AG ADR (NVS) trades at $140.03. Equity Rank's blended model fair value estimate across 9 valuation models with sufficient data is $137.16 — a model fair value differential of 2.0% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.

| Metric | Value |
|---|---|
| Current price | $140.03 |
| Model fair value estimate | $137.16 |
| Margin-of-safety differential | -2.0% |
| Models placing fair value above the current price | 4 of 9 |
| Fundamental Strength (0–100) | 76.5 (grade A-) |
| Next earnings report | 2026-10-27 (before market open) · analyst consensus EPS estimate $2.24 |
| Last recomputed | 2026-09-18 |

## How to quote this page

Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/NVS. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Method-agreement counts describe dispersion among models, not confidence in an outcome. Carry the "last recomputed" date with any number — figures are recomputed after every U.S. market close.

## How NVS's valuation models agree

Equity Rank computed model fair value for NVS from 9 independent valuation methods with sufficient data. 4 place fair value above the current price of $140.03, and 5 place it below. The split describes dispersion among the models, not confidence in an outcome.

## How the estimate is computed

Equity Rank runs 19 valuation methods (8–15 per security depending on data availability) — including discounted cash flow, Graham Number, price-to-free-cash-flow, Earnings Power Value, three-stage DCF, dividend discount, residual income, and justified price-to-book — and blends the individual outputs into one estimate, weighting each method by its trailing accuracy in the Drug Manufacturer sector. Method definitions: https://www.equity-rank.com/methodology · glossary: https://www.equity-rank.com/glossary.

## Related

- All Healthcare stocks with model fair values: https://www.equity-rank.com/stocks/sector/healthcare
- Peers: JNJ (https://www.equity-rank.com/stocks/JNJ.md), UNH (https://www.equity-rank.com/stocks/UNH.md), PFE (https://www.equity-rank.com/stocks/PFE.md), ABBV (https://www.equity-rank.com/stocks/ABBV.md), MRK (https://www.equity-rank.com/stocks/MRK.md)
- Machine access: MCP server https://api.equity-rank.com/mcp · public JSON https://api.equity-rank.com/api/stocks/NVS/public · https://www.equity-rank.com/developers

Equity Rank is not a registered investment adviser. Every figure on this page is algorithmic model output under stated assumptions, for informational and educational purposes only — not investment advice, not a target price, and not a forecast of results.